Clinical trial · no report yet · Phase 1/Phase 2
ARCHER
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
- NCT05950139 ↗
- Recruiting
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- NSCLC Stage IV; ALK Fusion Protein Expression
- Interventions
- Peptide vaccine
- Arms
- Advanced ALK+ NSCLC · Experimental
- Enrollment
- 12 (estimated)
- Primary outcomes
- Incidence of treatment-related adverse events
- Vaccine-specific immune response
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins with Oncovir, Inc.
- Start
- May 13, 2024
- Primary completion
- Jul 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05950139 · updated Jul 28, 2026